BioAtla Inc
BioAtla Inc logo
BCAB

BioAtla Inc (BCAB)

$3.62.17%

Market is closed
– opens on 8 PM, 31 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$3.521
Day's Range
$3.6901
$2.01
52-Week Range
$12.15
1 month return55.45%
3 month return47.75%
1 year return62.34%
5 year return88.39%

Analyst Recommendation

based on 13 analysts ratings

Buy
84%
Buy
15%
Hold
0%
Sell

Based on 13 Wall street analysts offering stock ratings for BioAtla Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 626.11%

Current

$3.6

Target

$26.14

Recommendation Trend

Based on 13 analyst

Current1M Ago3M Ago
Buy
11
5
11
Hold
2
0
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization170.4M
Book Value$3.8
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-2.84
Wall Street Target Price26.14

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)2.58
Enterprise Value194.8M
Enterprise Value/Revenue134.37
Enterprise Value/Ebitda-1.93

Technicals

Beta0.63
50 Day MA7.59
200 Day MA5.96

Institutional Holdings

Soleus Capital Management, L.P.

9.04%

Cormorant Asset Management, LLC

5.8%

HHG PLC

5.78%

TANG CAPITAL MANAGEMENT LLC

5.23%

Candriam Luxembourg S.C.A.

5.08%

Morgan Stanley - Brokerage Accounts

4.38%

Company Information

BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow it to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment (TME), even when the target is also found in normal tissue, not only improves safety and thus therapeutic index but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.
OrganizationBioAtla Inc
Employees56
CEODr. Jay M. Short Ph.D.
IndustryHealthcare

Discover more

Frequently Asked Questions

What is BioAtla Inc share price today?

Can Indians buy BioAtla Inc shares?

How can I buy BioAtla Inc shares from India?

Can Fractional shares of BioAtla Inc be purchased?

What are the documents required to start investing in BioAtla Inc stocks?

What are today’s High and Low prices of BioAtla Inc?

What are today’s traded volumes of BioAtla Inc?

What is today’s market capitalisation of BioAtla Inc?

What is the 52 Week High and Low Range of BioAtla Inc?

How much percentage BioAtla Inc is down from its 52 Week High?

How much percentage BioAtla Inc is up from its 52 Week low?

What are the historical returns of BioAtla Inc?

Who is the Chief Executive Officer (CEO) of BioAtla Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*